Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain
Abstract Today the evaluation of unwanted immunogenicity is a key component in the clinical safety evaluation of new biotherapeutic drugs and macromolecular delivery strategies. However, the evolving structural complexity in contemporary biotherapeutics creates a need for on-going innovation in assa...
Guardado en:
Autores principales: | Derrick Johnson, Erica Simmons, Sanofar Abdeen, Adam Kinne, Elijah Parmer, Sherri Rinker, Jennifer Thystrup, Swarna Ramaswamy, Ronald R. Bowsher |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/96c6f914c2334dada702d38fc68654fe |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection
por: Abolfazl Jahangiri, et al.
Publicado: (2021) -
Potentials and limitations of microorganisms as renal failure biotherapeutics
por: Poonam Jain, et al.
Publicado: (2009) -
Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa
por: Yoshitake Sakae, et al.
Publicado: (2017) -
Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc.
por: Mirko Cortese, et al.
Publicado: (2012) -
Clinical Severity of Visceral Leishmaniasis Is Associated with Changes in Immunoglobulin G Fc N-Glycosylation
por: Luiz Gustavo Gardinassi, et al.
Publicado: (2014)